Close Menu

Freenome

The company enters a race to the clinic with several direct competitors, including Guardant Health and CellMax Life, as well as other firms pursuing multi-cancer screening.

Research is accumulating for the improved performance of epigenetic signals over mutations, with multiple commercial efforts well underway.

Catch It Early

CNBC reports on firms pursuing blood tests to detect early-stage cancer.

The company believes the multi-omic approach it has honed for early cancer detection can also glean predictive signatures of drug response from both tumor and immune signals.

The companies will use Freenome's platform to identify cancer patients who are most likely to respond to treatment with ADC's loncastuximab tesirine.

The firm will use the funding to begin a validation study of its blood-based test for early detection of colorectal cancer. 

The company presented new data on the performance of a multi-pronged liquid biopsy assay in detecting colorectal cancers across a range of clinical stages.

The company presented a poster at the ACG meeting this week that reported over 80 percent sensitivity in a retrospective cohort with a majority of early-stage cancers.

The partners have established a laboratory to investigate cell-free DNA and other bloodborne molecules as cancer biomarkers.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.